Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 4/20 | 0.41 |
| ▸ | PDE4A | P27815 | 5/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.36 |
| ▸ | PI4KA | P42356 | 2/20 | 0.36 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.36 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.36 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.33 |
| ▸ | PRKCI | P41743 | 1/20 | 0.33 |
| ▸ | PDE5A | O76074 | 1/20 | 0.32 |
| ▸ | PDE1A | P54750 | 1/20 | 0.32 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.32 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27631272 | 0.89 | PDE4A (0.38) | XDHPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL27631267 | 0.86 | XDH (0.39) | XDHPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4465473 | 0.85 | XDH (0.48) | XDHPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4467324 | 0.85 | PI4KA (0.48) | XDHPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL4474039 | 0.84 | XDH (0.48) | XDHPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4466877 | 0.83 | XDH (0.50) | XDHPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL4465552 | 0.83 | XDH (0.40) | XDHPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4474196 | 0.83 | RXRA (0.41) | XDHPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL4463439 | 0.81 | XDH (0.38) | XDHPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4477491 | 0.81 | NR1H2 (0.42) | XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325982-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN T | 2009-12-31 | — | — | US | claimed |
| US-20080269260-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN T | 2008-10-30 | — | — | US | claimed |
| CN-100415747-C | Phosphodiesterase 4 inhibitors | MEMORY PHARM CORP (US) | 2008-09-03 | — | — | CN | claimed |
| US-7335654-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-02-26 | — | — | US | claimed |
| CN-1688578-A | Phosphodiesterase 4 inhibitors | MEMORY PHARM CORP (US) | 2005-10-26 | — | — | CN | claimed |
| US-20040102460-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. | 2004-05-27 | — | — | US | claimed |
| US-20090325982-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN T | 2009-12-31 | — | — | US | disclosed |
| WO-2009067607-A2 | COMBINATIONS OF PDE4 INHIBITORS AND ANTIPSYCHOTICS FOR THE TREATMENT OF PSYCHOTIC DISORDERS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-05-28 | — | — | WO | disclosed |
| US-20080269260-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN T | 2008-10-30 | — | — | US | disclosed |
| CN-100415747-C | Phosphodiesterase 4 inhibitors | MEMORY PHARM CORP (US) | 2008-09-03 | — | — | CN | disclosed |
| US-7335654-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-02-26 | — | — | US | disclosed |
| CN-1688578-A | Phosphodiesterase 4 inhibitors | MEMORY PHARM CORP (US) | 2005-10-26 | — | — | CN | disclosed |
| EP-1551837-A1 | PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceutical Corporation (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20040102460-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. | 2004-05-27 | — | — | US | disclosed |
| WO-2004014911-A1 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269260-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE3B, PDE3A | XDH 226/4885PDE4A 1/4885PDE4B 5/4885 |
| US-20040102460-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE3A, PDE3B | XDH 259/4885PDE4A 1/4885PDE4B 5/4885 |
| US-20090325982-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE3B, PDE3A | XDH 226/4885PDE4A 1/4885PDE4B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.